首页> 外文学位 >Development of a structure-based drug design module for a bioengineering lab.
【24h】

Development of a structure-based drug design module for a bioengineering lab.

机译:为生物工程实验室开发基于结构的药物设计模块。

获取原文
获取原文并翻译 | 示例

摘要

This thesis is focused on the development of a laboratory module for structure-based drug design. The process of structure-based drug design is thoroughly explored and simplified into five steps involving choosing the target, visualizing the target structure, identifying the binding site, docking the ligands, and evaluating them. The drug design for osteoarthritis was performed using the COX-2 enzyme as the drug target. Five ligand compounds, acetyl salicylic acid, rofecoxib, celecoxib, SC-558, and fucoxanthin were docked to the drug target individually with the help of UCSF DOCK software. Three ligands (rofecoxib, celecoxib, SC-558) unambiguously showed selective affinity for COX-2. The docked ligands, when evaluated using Lipinski's analysis, showed less absorption capabilities with increase in molecular weight and partition coefficient.
机译:本文致力于基于结构药物设计的实验室模块的开发。对基于结构的药物设计过程进行了彻底的探索,并将其简化为五个步骤,包括选择靶标,可视化靶标结构,识别结合位点,对接配体并对其进行评估。骨关节炎的药物设计是使用COX-2酶作为药物靶标进行的。借助UCSF DOCK软件,将五个配体化合物,乙酰水杨酸,罗非考昔,塞来昔布,SC-558和岩藻黄质分别对接至药物靶标。三种配体(罗非考昔,塞来昔布,SC-558)明确显示出对COX-2的选择性亲和力。当使用Lipinski的分析评估时,对接的配体随着分子量和分配系数的增加显示出较低的吸收能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号